Exploring President Biden's concerns about excessive drug prices and the impact of 'marching in' authority. Discussion on factors behind high drug prices, patents in the pharmaceutical industry, and the challenges of drug development. Analysis of Joe Biden's proposal to lower drug prices and the potential consequences for pharmaceutical companies.
The perception of excessive drug prices in the US raises questions about the impact of government intervention in granting companies the ability to produce patented drugs.
Addressing government insurance systems and increasing price sensitivity among consumers may help restrain drug prices.
Deep dives
High Drug Prices: President Biden's Concern
President Biden's concern about high drug prices is rooted in the perception that drug prices in the United States are excessive. These prices are often compared to those in other countries or to previous prices within the U.S. Market, and sometimes see significant spikes even for drugs that have been on the market for a while. The inequity arises when drug manufacturers rely on government-funded research for the basic knowledge to develop drugs and then profit from them by setting high prices. While this concern is valid, it raises questions about the impact of government intervention in granting multiple companies the ability to produce patented drugs.
Costs of Drug Development and the Role of Patents
The cost of developing a new drug, taking into account research and development (R&D) costs, clinical trials, and the many drugs that never make it to market, can range from $1.5 to $2 billion per approved drug. Only a small percentage of the drugs that enter clinical trials actually make it to market. The patent system plays a crucial role in protecting companies' profits and recouping the substantial investment required for drug development. Without patents or similar protections, drug makers would not recover the massive upfront costs, and innovation in certain areas, such as new antibiotics, may be stifled.
Exploring Alternatives to the Patent System
While the patent system contributes to incentivizing pharmaceutical innovation, it is not without flaws. There are alternative proposals, such as the use of prizes for innovation or public funding of research and development, which would reduce the reliance on high drug prices to recoup costs. However, it is important to acknowledge that the patent system alone is not solely responsible for high drug prices. Government policies, like insurance systems that detach consumers from price sensitivity, play a significant role in driving up drug prices. Addressing these policies and increasing price sensitivity among consumers could help restrain drug prices.
Does "march in" authority have hope for bringing drug prices down? Should it? What are the secondary effects of changing who can produce what drugs? Cato's Michael Cannon and Peter Van Doren comment.